diabetes
Regeneron’s Eylea smashes Phase 3 trial goal in diabetic retinopathy
March 20, 2018Manufacturing and Production, Research and Development Eylea, Regeneron, diabetes, pharma
Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a …
Study reveals “concerning” low standards of type 2 diabetes drugs in India
March 7, 2018Research and Development India, diabetes, pharma, regulatory, type 2 diabetes
In what they believe is the first study of its kind, a team of researchers at the University of Massachusetts …
Study identifies five kinds of diabetes, potentially changing treatment
March 2, 2018Medical Communications, Research and Development biotech, diabetes, drugs, pharma, pharmaceutical
A decade-long study has unearthed findings that could entirely change how people living with diabetes are treated, after the classic …
Novo Nordisk delivers in much-anticipated oral semaglutide diabetes trial
February 23, 2018Medical Communications, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes
Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …
Roivant signs $600m licensing deal with Poxel
February 13, 2018Manufacturing and Production, Sales and Marketing Poxel, Roivant, diabetes, imeglimin, pharma
Roivant Sciences has announced that it has entered into a licensing partnership with Poxel to develop and commercialise the latter’s …
Novo’s Ozempic secures European approval in type 2 diabetes
February 12, 2018Sales and Marketing EC, EMA, Europe, Novo Nordisk, diabetes, pharma
Novo Nordisk has revealed that its drug Ozempic (semaglutide) has received approval from the European Commission (EC) as a monotherapy …
MSD and Pfizer receive approval for combo diabetes therapy
December 21, 2017Sales and Marketing MSD, Pfizer, biotech, diabetes, drugs, pharma, pharmaceutical
MSD (known as Merck in North America) and Pfizer have announced that their sodium-glucose co-transporter 2 (SGLT2) inhibitor has received …
Novartis, Abbott targeted by Indian watchdog over allegations of price collusion
December 14, 2017Sales and Marketing Abbott, Emcure Pharma, Galdus, Novartis, USV, diabetes, pharma, vildagliptin
Novartis, Abbott, Emcure Pharma and USV have become the targets of an investigation by the Competition Commission of India (CCI) …
FDA approves first short-acting, follow-on biologic of Lilly’s Humalog insulin product
December 12, 2017Manufacturing and Production, Sales and Marketing Admelog, FDA, Humalog, Sanofi, diabetes, insulin, pharma
The FDA has announced its approval of Sanofi’s Admelog (insulin lispro), the first follow-on biologic version of Eli Lilly’s Humalog …
Study reveals diet able to reverse diabetes in half of patients
December 6, 2017Research and Development biotech, diabetes, drugs, pharma, pharmaceutical
Building on their previous research emerging from Professor Roy Taylor’s work at Newcastle University, a study has found that 45.6% …
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies
December 5, 2017Manufacturing and Production, Research and Development Novo Nordisk, Tresiba, Xultophy, diabetes, pharma
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …
Type 1 diabetes misunderstood as “disease of childhood”
December 1, 2017Medical Communications biotech, diabetes, drugs, pharma, pharmaceutical
New research published in The Lancet has revealed that type 1 diabetes cannot be understood as a “disease of the …
Psoriasis patients at greater risk of type 2 diabetes, study reveals
November 15, 2017Research and Development diabetes, pharma, psoriasis, type 2 diabetes
Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk …
Sanofi Q3 results disappoint due to waning diabetes sales
November 2, 2017Sales and Marketing Lantus, Sanofi, diabetes, pharma
Sanofi readjusted its 2017 financial expectations after its third-quarter results came in lower than projected. The company revealed that net …
Sanofi launches patent infringement lawsuit against Mylan over diabetes pen
October 25, 2017Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma
Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …
Latest content
